Guggenheim keeps USD 143 target for Rhythm Pharmaceuticals stock

Published on 10/20/2026 at 19:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 revenue hit USD 71.26 million, up 46.90 percent. Rhythm Pharmaceuticals stock costs EUR 80.25 on October 20, 2026, up 2.49 percent on Nasdaq.

Analyst target and results date

Guggenheim reiterated a USD 143.00 target and Buy rating for Rhythm Pharmaceuticals on October 19, 2026.
Second-quarter 2026 revenue reached USD 71.26 million, up 46.90 percent year over year.
Rhythm Pharmaceuticals stock costs EUR 80.25 at Lang & Schwarz on October 20, 2026 at 7:09 p.m. CEST, while Nasdaq shares gained 2.49 percent.
The next earnings report is scheduled for November 3, 2026.

RYTM, US76243J1051, Illustration mit AI erstellt.

Rhythm Pharmaceuticals (ISIN US76243J1051) drew a fresh bullish analyst view on October 19, 2026, when Guggenheim reiterated a Buy rating and a USD 143.00 price target, according to Markets Insider. At Lang & Schwarz, the stock was EUR 80.25 on October 20, 2026 at 7:09 p.m. CEST.

Revenue gives the target a base

Rhythm reported USD 71.26 million in global net product revenue for the second quarter of 2026, up 46.90 percent from the second quarter of 2025. The result came from IMCIVREE, the company's commercial treatment for rare forms of obesity. Simply Wall St reported that quarterly revenue exceeded analyst estimates by 5.30 percent, while adjusted earnings per share remained negative at USD 0.73.

What does the target imply?

The USD 143.00 target stands 58.13 percent above the Nasdaq price of USD 90.43 at 1:14 p.m. ET on October 20, 2026. That comparison matters because the target is based on the company's US-listed share price, while the German indication is quoted in euros. The Nasdaq session showed a 2.49 percent gain for RYTM on the same date.

Price position and next date

Rhythm's current USD 74.50 to USD 122.20 52-week range places the Nasdaq price 26.00 percent below its high and 21.35 percent above its low. Its market capitalization was USD 6.23 billion on October 20, 2026, and the stock traded 17.70 percent below its 52-week high on the latest annual view. Metacap lists November 3, 2026 as the next earnings date, with analysts expecting a loss of USD 0.68 per share.

Comparison with peers

Rhythm Pharmaceuticals: Nasdaq, USD, up 2.49 percent, price-to-earnings ratio minus 29.07, market capitalization USD 6.23 billion.

Arcus Biosciences: Nasdaq, USD, up 7.11 percent, price-to-earnings ratio minus 6.02, market capitalization USD 2.98 billion.

Viking Therapeutics: Nasdaq, USD, up 4.47 percent, price-to-earnings ratio minus 5.61, market capitalization USD 3.33 billion.

Trading remains tied to execution

For investors, the central tension is clear: quarterly revenue is growing quickly, but the company is still loss-making and the valuation depends on broader commercial adoption of IMCIVREE. Rhythm also continues developing additional MC4R medicines, leaving the November report as the next dated test of revenue growth and operating discipline.

The stock was trading at EUR 80.25 at Lang & Schwarz on October 20, 2026 at 7:09 p.m. CEST, while Nasdaq shares were up 2.49 percent on the day. The further course of trading is shown by the continuously updated real-time quote of Rhythm Pharmaceuticals stock.